What the company does
Human retinal progenitor cells (hRPC)
Human retinal progenitor cells differentiate into components of the retina.
Reneuron has developed the ability to scale up the manufacturing of hRPCs using a patented low-oxygen cell expansion technology.
The hRPC cell therapy candidate is being evaluated in an ongoing phase I/IIa clinical trial in the US in subjects with a blindness-causing inherited retinal disease, retinitis pigmentosa (RP).
CTX Cells
CTX cell therapy candidate is a treatment for patients left disabled by the effects of a stroke.
Reneuron’s product is a standardised, clinical and commercial-grade cell therapy product capable of treating all eligible patients presenting with the diseases targeted, without the need for additional immunosuppressive drug treatments.
Data from the Phase II PISCES trial indicated CTX therapy was safe and well-tolerated and produced clinically meaningful and sustained improvement in the level of disability and dependence as well as motor function.
Exosome platform
Exosomes are nanoparticles, released by cells, and contain a number of active proteins and micro RNAs, which are short non-coding RNAs capable of regulating gene expression, that are believed to play a key role in cell-to-cell communication.
ExoPr0, Reneuron’s first CTX-derived exosome therapeutic candidate, has demonstrated potential as both a novel therapeutic candidate as well as a drug delivery vehicle
How it is doing
In January, it completed dosing of the first group of three people in its phase IIa extension study of its human retinal progenitor cell therapy for degenerative eye disease.
This part of the trial will assess the responses of nine sufferers of retinitis pigmentosa – but at higher doses than the first ten subjects already treated. Data will be presented later this year.
ReNeuron said there would be a review of the short-term safety data from this first cohort before the next group is dosed.
In December, the US Patent and Trademark Office (USPTO) granted it a patent entitled: "Low oxygen culture conditions for maintaining retinal progenitor cell multipotency".
It will protect both the composition of its hRPC cell-based therapy candidate and its method of use. As such, ReNeuron said it constitutes a “principal layer of intellectual property” pertaining to its retinal disease programme.
What the boss says: Olav Hellebø, chief executive
"We are extremely pleased to have completed dosing of the first subject cohort in the extended phase IIa clinical study with our hRPC cell therapy candidate in RP patients."
“We are excited that one of the subjects was treated at a new clinical site in the US and we hope to add further new clinical sites shortly. The study continues to proceed according to plan."
Video
